PT0511 for KRAS-mutated or amplified advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing clinical trials.
This trial tests a new drug called PT0511 that targets a specific gene change (KRAS) found in some advanced solid tumors. It's for people whose cancer has not responded well to other treatments and who are looking for a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer is advanced (has spread) and is a type called a solid tumor (not a blood cancer).
- Your tumor has a specific gene change called a KRAS mutation or extra copies of the KRAS gene.
- You have already tried at least 1 cancer treatment but no more than 4 different treatments.
- Your cancer can be measured on scans (like a tumor that shows up clearly).
- You are in good general health (able to do daily activities with little or no help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called PT0253 for people with advanced solid tumors that have a specific genetic change (KRAS G12D). The drug aims to target and slow down the growth of cancer cells with this mutation.
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug, QLC1101, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It may be an option if you have tried other treatments or cannot take them.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
This study tests an experimental drug (RX001) given directly into tumors for people with advanced lung cancer that has a KRAS mutation. It is a phase 1 trial, so the main goal is to check safety and find a good dose.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.